glycerylphosphorylcholine has been researched along with Cognitive Dysfunction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chul Youn, Y; Han, SH | 1 |
| Androsova, LV; Gavrilova, SI; Kolykhalov, IV | 1 |
| Amenta, F; Sagaro, GG; Traini, E | 1 |
| Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L | 2 |
| Choi, BY; Choi, HC; Kho, AR; Kim, JH; Lee, SH; Sohn, M; Song, HK; Suh, SW | 1 |
1 review(s) available for glycerylphosphorylcholine and Cognitive Dysfunction
| Article | Year |
|---|---|
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.
Topics: Cognition; Cognition Disorders; Cognitive Dysfunction; Donepezil; Glycerylphosphorylcholine; Humans; Randomized Controlled Trials as Topic | 2023 |
2 trial(s) available for glycerylphosphorylcholine and Cognitive Dysfunction
| Article | Year |
|---|---|
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Topics: Aged; Aged, 80 and over; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Glycerylphosphorylcholine; Humans; Nimodipine; Quality of Life | 2021 |
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial.
Topics: Aged; Calcium Channel Blockers; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia, Vascular; Drug Therapy, Combination; Female; Glycerylphosphorylcholine; Humans; Male; Middle Aged; Nimodipine; Randomized Controlled Trials as Topic | 2020 |
3 other study(ies) available for glycerylphosphorylcholine and Cognitive Dysfunction
| Article | Year |
|---|---|
Quantitative electroencephalography changes in patients with mild cognitive impairment after choline alphoscerate administration.
Topics: Biomarkers; Cognition; Cognition Disorders; Cognitive Dysfunction; Electroencephalography; Glycerylphosphorylcholine; Humans | 2022 |
[Clinical and immunological effects of choline alfoscerate in the treatment of amnestic type Mild Cognitive Impairment].
Topics: Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Glycerylphosphorylcholine; Humans; Middle Aged; Neuropsychological Tests | 2022 |
Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment.
Topics: Animals; Blood-Brain Barrier; Cell Death; Choline O-Acetyltransferase; Cognition; Cognitive Dysfunction; Disease Models, Animal; Glycerylphosphorylcholine; Hippocampus; Male; Maze Learning; Neural Stem Cells; Neurogenesis; Neurons; Neuroprotective Agents; Pilocarpine; Rats, Sprague-Dawley; Seizures | 2017 |